(PDF) Abstract C-A2-05: Pneumonia Risk Among COPD Patients

Abstract C-A2-05: Pneumonia Risk Among COPD Patients Using Fluticasone/Salmeterol Versus Other Inhaled Steroids and Bronchodilators Alone

Clinical Medicine and Research - United States

doi 10.3121/cmr.6.3-4.120

Full Text

Abstract

Available in full text

Categories

Date

December 1, 2008

Authors

Publisher

Marshfield Clinic Research Foundation

Related search

Pneumonia Risk in COPD Patients Receiving Inhaled Corticosteroids Alone or in Combination: TORCH Study Results

European Respiratory Journal

Respiratory Medicine

English

Cost-Effectiveness of Combination Fluticasone Propionate–salmeterol 250/50 Μg Versus Salmeterol in Severe COPD Patients

International Journal of COPD

Respiratory Medicine

Occupational Health

English

Improvement in Asthma Endpoints When Aiming for Total Control: Salmeterol/Fluticasone Propionate Versus Fluticasone Propionate Alone

Primary Care Respiratory Journal

English

The Relationship Among COPD Severity, Inhaled Corticosteroid Use, and the Risk of Pneumonia

Annals of the American Thoracic Society

Respiratory Medicine

English

Survival in COPD Patients After Regular Use of Fluticasone Propionate and Salmeterol in General Practice

European Respiratory Journal

Respiratory Medicine

English

Fluticasone Alone or in Combination With Salmeterol vs Triamcinolone in Asthma

Cardiovascular Medicine

Intensive Care Medicine

Respiratory Medicine

English

Regular Treatment With Salmeterol and Inhaled Steroids for Chronic Asthma: Serious Adverse Events

English

Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids

Journal of the American Medical Directors Association

English

Cost-Effectiveness of Salmeterol/Fluticasone Combination Therapy vs. Fluticasone Propionate in Japanese Asthmatic Patients

Yakugaku Zasshi

Pharmaceutical Science

English